INTERVIEW: Dr. Reddy’s CEO On Move From Curing Diseases To Managing Health (Part 2 of 2)
This article was originally published in PharmAsia News
Executive Summary
G.V. Prasad, the CEO of Dr. Reddy’s Laboratories Ltd. is known for his big picture views. In this second part of a freewheeling interview, Prasad shared his thoughts on diverse subjects, most striking of all was the vision to shift gears from curing diseases to managing health.
You may also be interested in...
Set On Competing With Merck And Roche, Dr Reddy's Labs Pins Hopes On CETP Drug
MUMBAI - Despite the odds against developing a robust pipeline of innovative drugs, Kallam Anji Reddy, founder and chairman of the $1.36 billion Dr. Reddy's Labs, refuses to give up the chase to discover new drugs
How Sanofi Is ‘Playing To Win’ In India, Watch Diabetes Space
Sanofi India managing director Rodolfo Hrosz talks to Scrip about the company’s refreshed India strategy including in the competitive diabetes segment, which is expected to see a flurry of new product activity. While Soliqua has hit the market, all eyes are also on Novo Nordisk’s Awiqli and Cipla’s partnered inhaled insulin in the wings.
Asia Deal Watch: Nippon Shinyaku Takes On Intractable Rare Disease With MiNA
Plus deals involving Incyte/CMS, Biocytogen/ABL, Bharat/Biofabri/Bilthoven, Dr. Reddy’s/Pharmazz, Veeda/Heads, Sosei Heptares/GSK, BioGeometry/Sanyou, Ono/Sibylla and Teijin/BioProjet